Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. reported proposed sales of Class A Common stock on a Form 144. The filing lists multiple intended dispositions and recent sales; examples include Eric Lefkofsky selling 13,587 shares on 02/18/2026 and Blue Media, LLC selling 133,000 shares on 01/28/2026 and 02/19/2026.
Tempus AI, Inc. reports that ARK Investment Management LLC and Catherine D. Wood beneficially own 9,446,435 shares of common stock, representing 5.44% of the class. The filing shows ARK holds 8,836,759 sole voting power and 9,446,435 sole dispositive power; Catherine D. Wood holds 9,022,332 shared voting power and 9,446,435 shared dispositive power.
The form is signed by Kellen Carter and Catherine D. Wood with a signature date of 03/06/2026.
Tempus AI, Inc. director David R. Epstein reported an open-market sale of 250 shares of Class A Common Stock. The shares were sold at a price of $50.69 per share on March 2, 2026. After this transaction, Epstein directly holds 25,801 shares of Tempus AI Class A Common Stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Tempus AI, Inc. Chief Financial Officer James William Rogers reported an open-market sale of 11,414 shares of Class A common stock at an average price of $50.69 per share. After this transaction on March 2, 2026, he directly owned 127,248 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2025.
TEM: Notice of proposed sale of Restricted Stock Units. The filing lists 13,583 Restricted Stock Units to be sold by the issuer with an effective date of 02/19/2026.
The filing also shows prior sales by James Rogers: 10,084 common shares sold on 02/19/2026 for $595,460.20 and 19,966 common shares sold on 12/11/2025 for $1,461,439.07.
TEM reported an insider sale filing to sell 870 restricted common stock units. The transaction is described as restricted stock units to be sold by the issuer on 03/01/2026.
The filing also lists a prior 10b5-1 sale of 370 common shares on 02/02/2026 with an aggregate value shown as 21,981.70.
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, reported beneficial ownership of 94,967 shares of Class A common stock in an initial insider filing. This amount includes 54,405 restricted stock units, which vest in scheduled installments through February 15, 2028, and 20,000 shares certified as earned from performance-based stock units granted on August 7, 2025. The performance-based units are scheduled to vest on August 15, 2026 after the board certified achievement of the required performance metrics on February 20, 2026.
Tempus AI, Inc. outlines in its Annual Report how it uses artificial intelligence to build “Intelligent Diagnostics” that connect lab results with each patient’s clinical data to guide treatment decisions. The company has two main product lines: Diagnostics (oncology, hereditary and other tests) and Data and applications (including Insights, Trials, Next and Algos).
Its Platform aggregates multimodal data at scale through more than 700 data connections and over 5,000 healthcare sites, producing de-identified datasets used by providers and 19 of the 20 largest pharmaceutical companies. As of December 31, 2025, contracts in its data business had Remaining Total Contract Value of more than $1.1 billion, including approximately $300.0 million of potential opt-ins, and Net Revenue Retention for Insights was about 126%.
The report highlights expansion beyond oncology into neurology and cardiology, a growing suite of algorithmic diagnostics, and acquisitions such as Ambry Genetics, Arterys and Paige to deepen hereditary testing and imaging capabilities. The aggregate market value of non‑affiliate equity was approximately $11.0 billion as of June 30, 2025, and there were 173,729,901 Class A and 5,043,789 Class B shares outstanding as of February 20, 2026.
Tempus AI reported very strong growth for Q4 and full-year 2025 while remaining unprofitable on a GAAP basis.
Revenue rose 83.4% in 2025 to $1.27 billion, driven by Diagnostics revenue of $955.4 million (up 111.5%) and Data and Applications revenue of $316.4 million (up 30.9%). Q4 revenue reached $367.2 million, also up 83.0% year over year, with gross profit of $237.7 million.
The company posted a 2025 net loss of $245.0 million but improved Adjusted EBITDA to -$7.4 million, including positive Q4 Adjusted EBITDA of $12.9 million. Tempus ended 2025 with $759.7 million in cash and marketable securities, Total Remaining Contract Value above $1.1 billion, and Net Revenue Retention of 126%. For 2026, Tempus guides to revenue of about $1.59 billion and Adjusted EBITDA of roughly $65 million.
Tempus AI, Inc. director, CEO and Chairman Eric P. Lefkofsky reported a mix of stock awards and sales involving Class A Common Stock. He acquired 263,430 shares at no cost through a grant that includes fully vested restricted stock units and performance-based stock units certified as earned.
Entities associated with Lefkofsky, including Gray Media, LLC and Blue Media, LLC, sold a combined 179,837 shares in open-market transactions under a Rule 10b5-1 trading plan. In addition, 13,587 directly held shares were sold to cover statutory tax withholding obligations tied to vesting of restricted stock units, a mandated sell-to-cover transaction rather than a discretionary sale.